Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

This study targets an adult population of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), who have failed after a first line of treatment with pembrolizumab associated or not with chemotherapy and having an indication for a second line of treatment. Patients will be recruited in France in medical oncology departments. The main objective is to evaluate the objective response rate of PCC in patients with HNSCC with locoregional and/or distant 2nd line metastatic disease after failure of pembrolizumab +/- chemotherapy. The secondary objectives of the st

Trial Details

NCT ID
NCT06725368
Phase
PHASE2
Sponsor
Centre Paul Strauss
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • PCC
Locations (sample)
  • Ars-Laquenexy, France|49.09377,6.26989
  • Besançon, France|47.24878,6.01815
  • Colmar, France|48.08078,7.35584
  • Strasbourg, France|48.58392,7.74553
  • Vandœuvre-lès-Nancy, France|48.66115,6.17114

Key Eligibility Criteria

  • Age greater than or equal to 18 years at inclusion
  • Cytological or histological confirmation of the diagnosis of invasive squamous cell carcinoma of the head and neck
  • One of the following locations: oral cavity, oropharynx (known p16 status), larynx or hypopharynx
  • Cancers of unknown primary (CUP) of the head and neck are accepted

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →